# A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)

> **NCT07742215** · PHASE3 · RECRUITING · sponsor: **Biocad** · enrollment: 390 (estimated)

## Conditions studied

- Myeloma Multiple

## Interventions

- **DRUG:** BCD-248 + daratumumab
- **DRUG:** Daratumumab + pomalidomide + dexamethasone

## Key facts

- **NCT ID:** NCT07742215
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-07
- **Final completion:** 2032-10
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07742215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07742215, "A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07742215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*